Table 1.
Patient characteristics of the discovery cohort
| Characteristics | No. (%) |
|---|---|
| No. of patients | 519 |
| Median age, years (range) | 64 (18–92) |
| Sex | |
| Male | 300 (57.8) |
| Female | 219 (42.2) |
| Cancer type | |
| Bladder cancer | 27 (5.2) |
| Esophagogastric cancer | 40 (7.7) |
| Head and neck cancer | 10 (1.9) |
| Melanoma | 148 (28.5) |
| Non-small-cell lung cancer | 294 (56.6) |
| Drug class | |
| CTLA-4, monotherapy | 142 (27.4) |
| PD-(L)1, monotherapy | 320 (61.7) |
| CTLA-4 + PD-(L)1, combination therapy | 57 (11.0) |
| Best overall response | |
| CR/PR | 126 (24.3) |
| SD | 137 (26.4) |
| PD | 252 (48.6) |
| NE | 4 (0.8) |
| Durable clinical benefit | |
| DCB | 165 (31.8) |
| NDB | 330 (63.6) |
| NE | 24 (4.6) |
| Median TMB, Mutation/Mb (IQR) | 7.14 (3.77–13.24) |
| TET1 status | |
| Mutant | 23 (4.4) |
| Wildtype | 496 (95.6) |
Abbreviations: CR complete response, CTLA-4 cytotoxic T-cell lymphocyte-4, DCB durable clinical benefit, IQR interquartile range, Mb megabase, NDB no durable benefit, NE not evaluable, PD progressive disease, PD-(L)1 programmed cell death-1 or programmed death-ligand 1, PR partial response, SD stable disease, TMB tumor mutational burden